Focus: Helios Cardio is a public biotechnology company focused on regenerative biologic matrices for cardiovascular and oncology indications. The company is in early-stage development with a lean pipeline concentrated on cardiac arrhythmia treatment.
Profile data last refreshed 51m ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Helios Cardio suits early-career scientists or manufacturing specialists comfortable with pre-commercial risk, but limited hiring breadth and pipeline depth present career growth constraints.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Helios Cardio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Helios Cardio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo